• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Flerie

20.50 SEK

-1.91 %

Less than 1K followers

FLERIE

NASDAQ Stockholm

Investment

Financials

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-1.91 %
-17.00 %
-33.06 %
-37.44 %
-38.67 %
-49.67 %
-57.40 %
-84.13 %
-91.07 %

InDex Pharmaceuticals is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company’s lead asset is the drug candidate cobitolimod, which is in late-stage clinical development for the treatment of moderate to severe ulcerative colitis – a debilitating, chronic inflammation of the large intestine. InDex has also developed a platform of patent-protected discovery stage substances, so-called DNA-based ImmunoModulatory Sequences (DIMS), with the potential to be used in the treatment of various immunological diseases. InDex is based in Stockholm, Sweden. The company’s shares (ticker INDEX) are traded on Nasdaq First North Growth Market Stockholm.

Read more
Market cap
1.95B SEK
Turnover
176.04K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Research
Webcasts
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
9/7
2026

Interim report Q2'26

15/10
2026

Interim report Q3'26

20/1
2027

Annual report '26

Regulatory press release6/15/2026, 8:45 AM

Stämmokommuniké från extra bolagsstämma i Flerie AB (publ) den 15 juni 2026 klockan 10:00

Flerie
Regulatory press release6/15/2026, 8:45 AM

Bulletin from the extraordinary general meeting of Flerie AB (publ) on 15 June 2026 at 10:00 CEST

Flerie
Press release6/5/2026, 8:20 AM

Fleries portföljbolag Xspray Pharma mottar CRL från FDA för Nilopki™

Flerie

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release6/5/2026, 8:20 AM

Flerie’s portfolio company Xspray Pharma receives CRL from FDA for Nilopki™

Flerie
Regulatory press release6/2/2026, 6:00 AM

SUBSTANSVÄRDE – 31 maj 2026

Flerie
Regulatory press release6/2/2026, 6:00 AM

NET ASSET VALUE – 31 May 2026

Flerie
Press release6/1/2026, 11:00 AM

Fleries portföljbolag Xintela rapporterar positiva resultat från klinisk studie med stamcellsprodukten XSTEM

Flerie
Press release6/1/2026, 11:00 AM

Flerie’s portfolio company Xintela presents positive results from clinical study with its stem cell product XSTEM

Flerie
Regulatory press release5/29/2026, 9:00 AM

Förändring av det totala antalet aktier och röster i Flerie AB (publ)

Flerie
Regulatory press release5/29/2026, 9:00 AM

Change in the total number of shares and votes in Flerie AB (publ)

Flerie
Regulatory press release5/28/2026, 1:34 PM

Finansinspektionen: Flaggningsmeddelande i Flerie AB

Flerie
Regulatory press release5/22/2026, 10:25 AM

Finansinspektionen: Flaggningsmeddelande i Flerie AB

Flerie
Press release5/20/2026, 8:00 AM

Fleries portföljbolag Prokarium presenterar positiva interimresultat från klinisk studie inom urinblåsecancer

Flerie
Press release5/20/2026, 8:00 AM

Flerie’s portfolio company Prokarium presents positive interim data from clinical study in bladder cancer

Flerie
Regulatory press release5/19/2026, 9:00 AM

KALLELSE TILL EXTRA BOLAGSSTÄMMA I FLERIE AB (PUBL)

Flerie
Regulatory press release5/19/2026, 9:00 AM

NOTICE OF EXTRAORDINARY GENERAL MEETING OF FLERIE AB (PUBL)

Flerie
Press release5/18/2026, 10:20 AM

Flerie slutför fondemission beslutad av årsstämman

Flerie
Press release5/18/2026, 10:20 AM

Flerie completes bonus issue resolved by the Annual General Meeting

Flerie
Press release5/11/2026, 6:30 AM

Fleries huvudägare avstår aktietilldelning – övriga ägares andel i bolaget ökar med cirka 15,5 procent

Flerie
Press release5/11/2026, 6:30 AM

Flerie’s majority owner waives share allocation – other owners’ stake in the company increases by approximately 15.5 per cent

Flerie